Skip to content

Antithrombotic Activities of a Novel Yoghurt Drink: a Postprandial Study

Antithrombotic Activities of a Novel Yoghurt Drink: a Postprandial Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05290883
Enrollment
5
Registered
2022-03-22
Start date
2021-05-14
Completion date
2021-08-25
Last updated
2022-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Diseases

Brief summary

The project aims to investigate the antithrombotic activity of the novel yoghurt drink enriched with polar lipids derived from ovine milk. The health claims the formulated novel or functional food on EFSA guidelines The scientific requirements for health claims related to antioxidants, oxidative damage and cardiovascular health and in a particular paragraph 5.4, Claims on reduced platelet aggregation Platelet hyperactivity and hypercoagulability states are more commonly observed in subjects with cardiovascular (CV) risk factors. Healthy subjects or participants at very low risk of CV disease normally have non-activated circulating platelets. Reducing platelet aggregation in subjects with platelet activation during sustained exposure to the food/constituent (e.g., four weeks) would be a beneficial physiological effect. Within this investigation, the postprandial effects of this novel yoghurt drink against platelet aggregation are going to be studied ex vivo in blood from healthy human subjects as described in previously established procedures.

Interventions

DIETARY_SUPPLEMENTNovel yoghurt drink containing Polar Lipids

Postprandial decreased platelet activation/aggregation in subjects, after the yoghurt drink consumption

Sponsors

University of Limerick
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* • Healthy subjects need to have their dietary and dairy intake within the range \[1-2 serves per week\]

Exclusion criteria

* Subjects will be excluded from the study if they are * Under medication and intake of dietary supplements * Treatment for blood clotting disorders or dyslipidaemia

Design outcomes

Primary

MeasureTime frameDescription
An investigation of anti-platelet or antithrombotic effect of novel yoghurt drink by platelet aggregometry0 mins (preprandially) to 240 mins (postprandially)An investigation of anti-platelet or antithrombotic effect of novel yoghurt drink by platelet aggregometry will be carried out. The postprandial effect of novel yoghurt drink will be studied by using a platelet aggregation method as per literature. The antithrombotic effect of yoghurt drink lipids will be studied, using PAF and TRAP as platelet aggregation mediators. The investigation will be based on the study-specific platelet aggregometry analysis. Subjects will come to the lab after overnight fasting and they will be provided yoghurt drink (200mL); the activation of their platelets will be monitored over a period of 4 hours (0 to 4 hours study with 1 hour check points).

Countries

Ireland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026